MX9705209A - Preparacion estabilizada de factor viii recombinante, libre de albumina, que tiene un bajo contenido de azucares. - Google Patents

Preparacion estabilizada de factor viii recombinante, libre de albumina, que tiene un bajo contenido de azucares.

Info

Publication number
MX9705209A
MX9705209A MX9705209A MX9705209A MX9705209A MX 9705209 A MX9705209 A MX 9705209A MX 9705209 A MX9705209 A MX 9705209A MX 9705209 A MX9705209 A MX 9705209A MX 9705209 A MX9705209 A MX 9705209A
Authority
MX
Mexico
Prior art keywords
factor viii
recombinant factor
sugar content
free recombinant
low sugar
Prior art date
Application number
MX9705209A
Other languages
English (en)
Other versions
MXPA97005209A (es
Inventor
Rajiv Nayar
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of MX9705209A publication Critical patent/MX9705209A/es
Publication of MXPA97005209A publication Critical patent/MXPA97005209A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion estable, libre de albumina, del factor VIII recombinante (rFVIII) en forma liofilizada que contiene tanto componentes cristalinos como así también amorfos, y que comprende, después de ser reconstituida con agua, aproximadamente 65 a 400 mM de glicina, hasta 50 mM de histidina, 15 a 60 mM de sucrosa, hasta 50 mM de NaCl, hasta 5 mM de CaCl2, y de 50 a 1500 IU/ml de rFVIII. Una formulacion muy preferida comprende, después de haber sido reconstituida con agua, alrededor de 290 mM de glicina, 20 mM de histidina, 30 mM de sucrosa, 30 mM de NaCl, 2.5 mM de CaCl2, y de 50 a 1500 IU/ml de rFVIII. El contenido de agua residual de la preparacion es de aproximadamente 1 a 3% en peso, de preferencia del 1% en peso.
MXPA/A/1997/005209A 1996-07-12 1997-07-10 Preparacion estabilizada de factor viii recombinante, libre de albumina, que tiene un bajo contenido de azucares MXPA97005209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US08678492 1996-07-12

Publications (2)

Publication Number Publication Date
MX9705209A true MX9705209A (es) 1998-05-31
MXPA97005209A MXPA97005209A (es) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
GR3033669T3 (en) 2000-10-31
ES2144293T3 (es) 2000-06-01
PL321058A1 (en) 1998-01-19
BR9704407A (pt) 2000-06-06
HUP9701191A3 (en) 2000-08-28
HUP9701191A2 (hu) 1999-06-28
RU2201252C2 (ru) 2003-03-27
JPH1067679A (ja) 1998-03-10
NZ328297A (en) 1999-09-29
SK92197A3 (en) 1998-02-04
DK0818204T3 (da) 2000-07-17
ID19074A (id) 1998-06-11
IL121273A0 (en) 1998-01-04
AR007845A1 (es) 1999-11-24
KR100491281B1 (ko) 2005-08-05
CO4700302A1 (es) 1998-12-29
AU718901B2 (en) 2000-04-20
US5763401A (en) 1998-06-09
MY125544A (en) 2006-08-30
TW381027B (en) 2000-02-01
EP0818204A3 (en) 1998-02-04
HU9701191D0 (en) 1997-08-28
DE69701548D1 (de) 2000-05-04
PT818204E (pt) 2000-08-31
CZ219497A3 (cs) 1998-01-14
CN1130224C (zh) 2003-12-10
SK282207B6 (sk) 2001-12-03
HU221415B1 (en) 2002-09-28
ZA976167B (en) 1998-02-02
JP4077055B2 (ja) 2008-04-16
PL186950B1 (pl) 2004-04-30
UA43882C2 (uk) 2002-01-15
CN1181974A (zh) 1998-05-20
US5874408A (en) 1999-02-23
IL121273A (en) 2000-09-28
SG50864A1 (en) 1998-07-20
EP0818204A2 (en) 1998-01-14
EP0818204B1 (en) 2000-03-29
AU2860497A (en) 1998-01-22
KR980008241A (ko) 1998-04-30
BR9704407B1 (pt) 2010-03-09
CA2210038C (en) 2007-03-13
TR199700628A2 (xx) 1998-01-21
CA2210038A1 (en) 1998-01-12
ATE191146T1 (de) 2000-04-15
CZ292183B6 (cs) 2003-08-13
DE69701548T2 (de) 2000-07-27

Similar Documents

Publication Publication Date Title
MY125544A (en) Stabilized albumin-free recombinant factor viii preparation having a low sugar content
RU97111733A (ru) Устойчивая, свободная от альбумина лиофилизованная композиция рекомбинантного фактора viii
PL313084A1 (en) Pharmaceutic formulation of nerve growth factor
CA2413334A1 (en) Stabilized interleukin 2
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
ES8704350A1 (es) Procedimiento para la preparacion de un conjugado bacteriano
AU4478093A (en) PEG-interferon conjugates
AU5649586A (en) Partially purified bone-inducing factor
GR3035067T3 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins.
HU9401831D0 (en) Stabilized pharmaceutical formulations comprising growth hormone and asparagine
WO1996009831A3 (de) Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
MXPA01005509A (es) Alimento para bebes estimulantes del crecimiento del timo.
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
DE69313444D1 (de) IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
JO1992B1 (en) Fixed pharmaceutical compounds based on the derivatives of quinpristine and dalphopristine materials and their preparation process
GB8926725D0 (en) Improvements in or relating to chairs
AU3004192A (en) Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process
DE69804674D1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
CA2247998A1 (en) Fragments of cr1 and their use
TH18150B (th) สารสำเร็จรูปของรีคอมบีแนนท์แฟคเตอร์ viii ที่ปราศจากอัลบิวมินชนิดที่ทำให้เสถียรแล้วซี่งมีปริมาณน้ำตาลต่ำ
AU3731689A (en) Improvements in or relating to electro-magnetically operable devices
AU590506B3 (en) Improvements in and relating to bow ties